Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients

2020 ◽  
Vol 46 (10) ◽  
pp. 1874-1881
Author(s):  
Xin Li ◽  
Xiaofei Li ◽  
Xiangning Fu ◽  
Lunxu Liu ◽  
Yang Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Survival Benefit ◽  
Small Cell ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
Multicenter Observational Study ◽  
Skip Metastases

Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: A GFPC study

Lung Cancer ◽  
2011 ◽  
Vol 74 (2) ◽  
pp. 264-267 ◽  
Author(s):  
A. Vergnenègre ◽  
I. Monnet ◽  
C. Chouaïd ◽  
J. Hureaux ◽  
J. Mazières ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Multicenter Observational Study ◽  
Erlotinib Therapy

A multicenter observational study of effectiveness and safety of nivolumab in non-small cell lung cancer in real clinical practice.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21092-e21092
Author(s):  
Juan Francisco Marín Pozo ◽  
Macarena Merino Almazán ◽  
Juan Manuel Duarte Pérez ◽  
Facundo Alberti Vargas ◽  
María Paz Quesada Sanz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Practice ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Multicenter Observational Study ◽  
Real Clinical Practice

scholarly journals Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yongliang Zhang ◽  
Yu Yao ◽  
Yaping Xu ◽  
Lifeng Li ◽  
Yan Gong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Chinese Patients ◽  
Plasma Samples ◽  
Small Cell Lung ◽  
Pan Cancer ◽  
Tumor Dna

AbstractCirculating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient’s genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document